OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
October 30, 2026
Earnings Call Speaker Segments
Kurt Gustafson
executiveThank you, operator, and good morning to all of you. Kurt Gustafson here, OmniAb's Chief Financial Officer — I appreciate everyone taking the time to join our conference call on third quarter 2026 financial results. Slides that go along with today's prepared remarks can be found in the investor section of our website, omniab.com. Before we get started, I want to remind listeners that remarks made on this call by OmniAb's management will contain forward-looking statements as defined under the federal securities laws. Such forward-looking statements carry risks and uncertainties that might cause actual results to differ materially from any anticipated results; these statements are qualified by the cautionary language in today's press release and in our SEC filings. Importantly, this conference call includes time-sensitive information that is accurate only as of the date of the live broadcast, today, October 30th, 2026. Except as required by law, OmniAb assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this call. With me this morning are Matt Foehr, OmniAb's President and CEO, and Amechi Nwachuku, our Chief Operating Officer. On today's call, Matt will cover some highlights, Amechi will give an update on our xPloration program, and I'll walk through our financial results and guidance, after which we'll open up the call to questions. With that, I'll hand the call over to Matt.
Matt Foehr
executiveThanks, Kurt. Good morning, everyone, and thank you for joining us for our third quarter call. I'll begin on slide 4, where we've included a few highlights from the third quarter. OmniAb's business has been structured to gain from revenue streams that are diversified, long-term, and durable. We kept delivering strong results in Q3, since our highly differentiated technology platforms are helping partnerships grow and programs advance. On the licensing front, we've been very active and remain so, and during the quarter we announced a major new deal with Eli Lilly covering a novel ion channel program. We felt a lot of enthusiasm about forming this significant fresh partnership with Lilly — clearly, their emphasis is on bringing medicines forward for substantial unmet medical requirements, and our distinctive know-how plus proven technologies tied specifically to ion channels leave us strongly placed to support that effort and propel this new discovery initiative ahead. That licensing arrangement gave us an upfront payment, and we can also earn as much as $370 million through research, development, and commercial milestones, plus possible tiered royalties on worldwide net sales. During Q3, partners in our expanding ecosystem used our differentiated technologies more, and we saw strong momentum for the xPloration platform along with consistent advancement in the programs our partners are moving through different development phases. Those points took center stage at the Investor and Analyst Day we hosted earlier this month, and we are very grateful to everyone who attended, whether in Emeryville or via the video webcast. At that event, we emphasized that xPloration—our AI-driven, high-throughput platform for screening single B cells—can now be accessed by every prospective client. That opens meaningful opportunities for our company, and Amechi will cover xPloration more thoroughly during his portion. In addition, we introduced OmniTides, a fresh peptide discovery service built on our OmniUltra transgenic chicken. OmniTides aims to deliver partners an integrated workflow spanning discovery through synthesis, with peptide manufacturing offered through qualified CROs, yielding naturally optimized peptides suited to a widening set of therapeutic uses that are expanding. Lastly, because our business keeps performing strongly, we have raised our 2026 outlook for revenue and cash once again. Kurt will go into more detail on our revised guidance when he speaks during his part of this morning's presentation. Turning to slide 5, the novel technologies we have at OmniAb strengthen our role as an important enabling technology licensing partner and back both current and new partnerships. These novel technologies, together with our capabilities and our industry vantage point, keep us at the leading edge of next-generation therapeutics discovery, and we believe they put us in position to generate meaningful value for our stakeholders. Slide 5 lays out our technology platform, arranged according to how we assist partners in efficiently creating, screening, and ultimately delivering novel therapeutics. During this quarter, we moved forward on key pieces of the platform, and I brought up OmniTides, which builds in in vivo optimization powered by biological intelligence — a phrase we came up with a few years ago. OmniTides puts biological intelligence to work early in discovery, and that can help programs move efficiently into chemical synthesis and, eventually, development. Our proprietary transgenic chicken-based technologies — OmniDab and OmniUltra specifically, which you can see on the left side of this slide — keep bringing in new partners and generating new programs. Our OmniDeep offering, which appears across the bottom of this slide and is our set of AI and machine learning tools integrated throughout our technology stack, also creates meaningful value; so too do the highly valuable novel data layers that we hold and are able to produce, which can open up considerable business opportunities for us as well. Let me quickly walk through some of our metrics now, beginning with slide 6. As of the close of the third quarter, our active partner count stood at 111, a net gain from 110 when the second quarter ended. Among the new licenses signed in Q3 were YmaBio Inc and Monash University, partly offset by one partner attrition event, which happened when one of our bigger partners bought one of our smaller ones; that sort of thing comes up occasionally, and on the whole we view it as a positive for assets discovered using our technologies. Our partner mix remains nicely diversified, and we're proud that 9 of the world's 10 largest pharmaceutical companies are now active OmniAb partners, which I believe speaks to the quality and strength of that partner base. Moving to slide 7, here you'll see our active programs metric. We finished the quarter with 433 active programs, compared with 407 when 2025 ended. That reflects 38 additions and 12 terminations so far this year; during the third quarter alone, we posted a net increase of 8 programs. Attrition is, naturally, a standard part of this business, as partners fine-tune their pipelines together with their investment and R&D priorities. Notably, contracted future economics to OmniAb apply to over 98% of our active programs, and across our portfolio we hold in excess of $3 billion in total contracted potential milestones, at an average royalty rate of about 3.4%. Turning to the clinical side, slide 8 presents our partners' active clinical programs and approved products. When Q3 ended, 34 programs in active clinical stages along with approved products were using our technologies. During 2026 to date, we have brought in 4 additional clinical programs, and we continue to anticipate fresh clinical entrants in the near term; those active clinical programs represent about $340 million in potential milestones still owed to OmniAb. Turning to slide 9, the graphic there shows the position of our partner pipeline at clinical and commercial stages as of September 30th, covering programs that still carry downstream economics for OmniAb. A program's placement on this graphic reflects how far it has progressed within a particular geography, market, or indication. On the right-hand side of this slide, we continue to list medicines that some of our partners regard as important potential first-in-class or best-in-class assets, and I'll go through several of them when I get to the next slide. I'd also point out that after Q3 ended — in fact, just last week — batoclimab, shown here on slide number 9 in the registration column in blue, was approved in China for treating generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. In China, batoclimab has become the fourth medicine cleared from our platform. When we next show this graphic with a full-year 2026 status, investors will spot among the progression updates that batoclimab has shifted to the right, joining the approved column. Now to slide 10, which calls out several recent advances in partner programs. The three programs starting on the left side of this slide — IMVT-1402, TEV-408, and pecetabart tocentecan — are each characterized as potential pipeline-in-a-product assets, carrying first-in-class or best-in-class potential. These programs are aimed at indications with considerable unmet medical needs, and their partners are strongly dedicated to moving them forward quickly. On the right side of this slide, you'll also see the approval update for batoclimab in China that I referenced earlier. To close out my portion on slide 11, we're highlighting what we see as OmniAb's value pillars. In our view, our differentiated discovery technologies, innovative capabilities, and expanding partnerships put us in position to generate durable, long-term value for our stakeholders. Our pipeline is growing, and our partnership base is broad, which underpins substantial contracted downstream milestones and royalties from a diversified basket of promising potential first-in-class and best-in-class programs—and at the same time gives us unique industry insights that continually shape our strategic priorities and the areas we focus on. On top of that, a growing set of novel discovery technologies—our chicken-based ones among them—is bringing in fresh partnerships and creating more ways to generate licensing value, today and down the road. What's more, our distinctive xPloration platform widens our reach and rounds out the discovery technology lineup we already have, while contributing lasting and substantial revenue streams to the business. We feel we're now in a very strong position to deliver for our stakeholders. With that, I'll turn things over to Amechi, who can say more about xPloration. Amechi?
Amechi Nwachuku
executiveThanks, Matt, and good morning to everyone. As Matt mentioned, we've expanded commercial availability for our xPloration platform. That move addresses an estimated market opportunity of more than $500 million, and it could unlock synergistic opportunities throughout OmniAb's business lines, at a time when the industry is recognizing the value of lab automation and large-scale data generation for discovery. xPloration is an innovative platform for B-cell screening. For teams working in antibody discovery, the xPloration platform provides value via greater throughput, simpler use, robustness, and reduced cost compared with existing methods. Since it launched, researchers at large pharma companies, global CROs, and specialty biotech firms have taken part in live demonstrations to find out what the xPloration instrument can do within their workflows. The response we've gotten has been uniformly encouraging, and that curiosity is now converting into orders—indeed, one more unit went to a leading worldwide big pharma in Q3. Both our expanding roster of qualified prospects and our own primary market research support what we project for xPloration. Turning to slide 14 and the business model, xPloration is a full platform offering several ways to generate revenue. It combines an instrument-led customer relationship with three recurring revenue streams. The instrument serves as the entry point. Each capital sale builds a wider and deeper connection with the customer and expands the installed base that underpins recurring revenue going forward. Beyond that, our proprietary chips and other consumables generate high-margin revenue based on usage, with each run bringing in income; as customers embrace the platform and conduct additional experiments, that revenue grows. Software contributes an additional recurring stream. Annual licenses underpin analysis and data management, deliver predictable revenue, and can grow in value as we introduce new workflows and applications. Service rounds out the model. Installation, training, and preventive maintenance help keep instruments running, support customer retention, and encourage repeat purchases, usually via multiyear contracts linked to the installed base. Combined, these revenue streams can provide OmniAb with a durable and complementary source of growth. Moving to slide 15, you can see that we anticipate xPloration revenue for 2026 will land between $2 million and $3 million. We anticipate xPloration's revenue will grow by 100% in 2027, and then grow by another 100% in 2028. As time goes on, we look for recurring revenue from consumables, software, and service to build up and turn into a long-term growth engine for the xPloration business, so that xPloration provides durable revenue streams. With that said, I'll hand the call over to Kurt for a discussion of our financials. Kurt?
Kurt Gustafson
executiveThanks, Amechi. I'll start with revenue, which is on slide 17. For Q3 of 2026, revenue landed at $4 million, compared with $2.2 million in the same quarter last year, and service and xPloration revenue drove most of that increase. Service revenue climbed on the back of work performed on antibody programs and ion channel programs. We signed new ion channel service agreements late last year and earlier this year, and those explain part of the uptick. One additional point worth noting: we expect service revenue from the Lilly collaboration to start contributing in Q4. Turning to slide 18, revenue for the 9-month period totaled $31.8 million, compared with $10.3 million for the equivalent stretch of 2025, with most of the increase linked to milestone revenue. Our partner programs have moved forward substantially this year, and that has varied quarter to quarter. Last year, milestone revenue was weighted heavily toward the back half, whereas this year it is loaded more toward the front end. Now on slide 19, you can see operating expense for the quarter. Total cost and operating expense was $20.4 million in each period. R&D expense declined this period and was partly offset by a modest increase in G&A expense plus other operating expense. Bear in mind that cost of sales falls within the other expense category, and part of this quarter's rise in that other bucket comes from higher cost of sales tied to greater instrument sales. Slide 20 shows year-to-date operating expense, which totaled $62.7 million, compared with $63.5 million a year earlier. The decline in both R&D and G&A expense reflects efficiencies we found in the business that brought costs down. Those lower operating costs were partly offset by an increase in other expense. Remember that last year we recorded a gain that reduced operating expense in that period. Earlier this year, we took a noncash write-off in the first quarter; those two line items distort the overall operating expense comparisons, and without those one-time items, the decrease would have been considerably larger. Slide 21 presents our P&L for the quarter and year-to-date. I've already walked you through revenue and operating costs, so I'll focus on the bottom line. Net loss for the third quarter was $15.7 million, or $0.12 per share, versus a net loss of $16.5 million, or $0.14 per share, in the year-ago period. Year-to-date, net loss improved to $29.3 million, or $0.23 per share, against a net loss of $50.6 million, or $0.46 per share, in the prior-year period. On slide 22, there's a reconciliation that takes our GAAP operating expense down to non-GAAP cash costs and operating expense, and it strips out the main noncash items — depreciation, share-based compensation, and amortization of intangibles. In our view, that measure gives a better read on what the business actually does, and the numbers stay fairly consistent across periods. Turning to the balance sheet, on slide 23, we ended the quarter with $64.2 million in cash and investments. You will also notice an increase in deferred revenue, and that stems from the upfront payment associated with the ion channel agreement signed during the third quarter. Typically, deferred revenue is amortized over the research terms of each agreement individually. Our updated 2026 financial guidance appears on slide 24: because of the higher milestone revenue we have delivered, we are raising guidance for both revenue and cash, while at the same time reducing our operating expense guidance, reflecting lower operating costs. The details are on the next slide. Slide 25 lets you compare current guidance against certain prior figures — total revenue is now expected to be $35 million to $39 million, raised from the previous $32 million to $36 million. Costs and operating expenses are now anticipated at $83 million to $87 million, which is $1 million lower than our prior guidance. Likewise, guidance for cash costs and operating expenses is being reduced by $1 million, to a range of $50 million to $54 million. On cash, we now expect a year-end balance of between $53 million and $57 million. We started the year with $54 million in cash, so on a net cash flow basis, we expect the business to be roughly break-even over the course of the year. 2026 has been a strong year for us. Our partners have made great progress, and that has driven milestone revenue higher. The xPloration business has gotten off to a good start, and we expect that momentum to continue. In addition, we have signed several new multiyear ion channel contracts, which has increased service revenue, and we hope to keep building on that. Combine those factors with a disciplined operating expense base, and we are well positioned going forward. With that, I would like to open the call for questions. Operator?
Puneet Souda
analystHey everyone, appreciate you taking the questions. So, first off, collaboration revenue came in strong this quarter, and that's even before the Lilly revenue kicks in. How much of that is really being fueled by uptake of OmniUltra and the other chicken models, and how should we be thinking about the timing of deferred revenue recognition?
Matt Foehr
executiveThanks, Puneet. I'll speak in general terms about the mix, and then Kurt can fill in any detail I leave out. On the cadence — it's a blend, right? What we've observed is that when we roll out new technologies, they bring in new partners and programs; with chicken-based programs, the partners clearly need to rely on us for that work. OmniDab and OmniUltra are both pulling in new partners and generating additional service work. Going back a bit, we signed some new ion channel deals late last year and earlier this year, and those are adding to service work too. As you mentioned, the Lilly deal was announced during the quarter. We anticipate it beginning to contribute in the fourth quarter, and it'll be a multiyear collaboration with Lilly. I hope that gives you the color you're looking for.
Puneet Souda
analystUnderstood — that's really useful. Regarding xPloration, you mentioned an additional placement there. Could you perhaps expand a little on how the commercial pipeline is taking shape? You spoke about doubling the numbers here. What might potentially push that even higher? Which drivers would bring it in line? And maybe if you could touch a little on the capital side — how are you engaging with customers, and how should we think about capital versus the recurring revenue consumables from xPloration?
Amechi Nwachuku
executiveThanks for the question. The starting point when it comes to xPloration platform sales is the capital side. What we're finding with our customers is that each of them runs a different capital budgeting process; that's the reason a pipeline for an instrument sale can run anywhere from 12 to 18 months. We build that relationship early, then we partner with our customers to get an instrument placed, and that is what gives us confidence to project the pipeline and state that we believe the business will double next year and the year after. Following that, the recurring revenue streams come into play as customers use the instruments and conduct various experiments.
Puneet Souda
analystI see, understood. Thanks for that. So perhaps I could quickly ask about batoclimab—how should we think regarding the royalty contribution from it? Should we anticipate a similar performance compared with the other China assets you've seen previously, or should we expect it to be somewhat higher? Thank you.
Matt Foehr
executiveThanks, Puneet. This is recent news from late last week. Harbour BioMed announced they had received NMPA approval for batoclimab in China for generalized myasthenia gravis in this set of patients who are anti-acetylcholine receptor antibody positive. Along with that, they stated they are looking to launch the drug soon. They were clear about preparing for that. It's probably still too early to know what pricing will be, etc., and how that will impact the royalty line, but I would just say stay tuned on that.
Puneet Souda
analystUnderstood, super. Congratulations on the quarter. Thank you, guys.
Matt Foehr
executiveThank you.
Amechi Nwachuku
executiveThanks, Puneet.
Srikripa Devarakonda
analystHi everyone, I really appreciate you taking the time to answer my question, and congratulations on how much progress you made this quarter. I've got a couple of things to ask. First, regarding the Teva partnership and TEV-408, does that positive celiac study shift the expected monetization timeline at all, and which upcoming development decisions might trigger further milestones? Any detail you can share on that would be useful, since you have both celiac and vitiligo development going on. I have one more question after this.
Matt Foehr
executiveSrikripa, thank you for asking; we were very happy with the data Teva presented in celiac. Speaking personally, I found it to be a remarkably well-constructed study, and I believe it demonstrates both the strength and the effectiveness of that drug. It was encouraging for us to see that; the company has been fairly open in its public presentations regarding the opportunity there, pointing to potential peak sales of roughly $1.5 to $2 billion from the celiac indication by itself. They have called attention to the Fast Track designation it holds, and they are pushing it ahead aggressively; seeing those data was genuinely pleasing to us. Beyond that, in vitiligo, Teva has stated publicly that it foresees peak sales potential of around a billion dollars there. They are advancing that program quickly as well. Beyond those two approved uses, people have also talked about TEV-408 possibly being used in additional conditions — alopecia areata, eosinophilic esophagitis, and atopic dermatitis. Each of these would meaningfully expand the number of patients the drug might reach. Seeing the celiac results was excellent, and we look forward to what lies ahead for that asset.
Srikripa Devarakonda
analystGreat, thanks a lot. That was solid data. Nice work on that. Perhaps one for Kurt. As you look toward the next stage of growth, I was just wondering how you're thinking about the incremental spending required to deliver that next phase, and as xPloration scales up, do you believe the current base can carry the growth you laid out, or should we be expecting meaningful step-ups in investment over the next year and two? Thanks.
Kurt Gustafson
executiveFor the core antibody business, I'd say we've assembled a team, and in fact, if you've been following us, we've managed to uncover efficiencies in that business. In our view, this business is appropriately sized to back the partnerships we have and those we will sign, along with the programs we have and the programs that will expand. We see no need to bring on more infrastructure for that portion of the business. With xPloration, we'll keep monitoring how that business develops, and if there are further investments required, we'll allocate them the same way we did this year; during this year, we did put additional money into xPloration, and we located savings elsewhere to reallocate those resources. We get together and make calls on where to put resources, and direct dollars to places where we believe we'll earn a good return. Broadly speaking, I wouldn't anticipate dramatic increases in our operating expense, given our projection of the operations we have.
Srikripa Devarakonda
analystGreat. Thanks very much.
Matt Foehr
executiveThanks, Josh. By way of background, OmniTides is the workflow we offer from discovery through synthesis, and we introduced it at our Investor Day a few weeks ago, built on our OmniUltra transgenic chicken. The brief answer is yes — it definitely draws partners in, and I'd describe them as deep collaborators along with others. There's genuinely been, I'd say, considerable expansion in peptide use, really pushed by the metabolic field, and naturally that's somewhere people have interest. Beyond metabolic, we're also seeing uses in a range of formats and modalities. We're pretty enthusiastic about OmniTides and the way it broadens our partner base, opening up, I'd say, the call file for our business development and licensing group to new participants, and we're watching that happen right now. We're genuinely excited about it. I believe it will diversify not just the partner base but also the therapeutic areas being pursued with our technologies. Great. On xPloration, I'm just curious about the customer mix. Given that you now have wider commercialization, what does that mix look like across smaller biotech, large pharma, and CROs?
Amechi Nwachuku
executiveInterest is coming in from each of those three groups. Feedback from the people running live demos, along with what's in our pipeline, covers input from discovery teams at large pharma, at CROs, and at small biotech. Clearly, this represents a bigger capital outlay for buyers, so the capacity to pay — to phrase it that way — varies according to the segment a customer belongs to; even so, interest is showing up, and we are getting placements across all three categories. Great, perfect. Thanks for the color.
Matt Hewitt
analystMorning, and well done on a solid quarter. I'd like to get a sense of what the milestone contribution might be for those 19 readouts you're expecting across the coming 15 months. Of course, I understand not every one will move forward to the next clinical stage or reach commercial approval, but I'm simply attempting to gauge what those milestones—or the overall milestone total—might look like, to give us a rough bracket for the milestone contribution over roughly the next 2 years.
Matt Foehr
executiveMatt, thank you. What you're referring to are the readouts we flagged a few weeks ago during our analyst event. Lined up we have a schedule of primary completion of clinical trials by partners that ranks as the busiest we have ever had, which is excellent, as we look ahead across the coming 18 months; those readouts, inside that pool of programs and partnerships, there's an aggregate—right, they sit within that aggregate of $340 million in potential milestone payments we're able to earn from those programs. That's a meaningful quantity of milestones; naturally each contract differs somewhat regarding how it's structured and when milestones get paid, but we feel terrific about that stream of news, that stream of data events, and really the confidence and the investment shown by our partners, who are advancing rapidly programs that were discovered using our technologies. I believe that speaks volumes about the value our technologies generate and, I'd say, the character of our partner base and its strength.
Matt Hewitt
analystGot it. Maybe I could put a question to Amechi about xPloration. I realize it's early days yet, and you've only just brought one additional system online, but from what you've seen with the first couple already in the field, what kind of consumable pull-through are you seeing? Would you say it's broadly consistent with your expectations? Are there things you can do to help customers get more out of the equipment? Any specifics or observations from these early days of the xPloration launch would be useful. Thank you.
Amechi Nwachuku
executiveI appreciate the question. It's too early for me to say things have settled down. I can't claim that yet. What I can say is that we've invested a great deal of effort working alongside our customers to make sure they have an excellent experience and that they run the instrument in whatever way serves them best. Of course, consumables pull-through will vary, right? It will differ, for instance, between an academia customer and a large pharma customer. Overall, the picture makes us optimistic and gives us confidence to say that we expect revenue to double in 2027, then continue growing and double again in 2028 — with roughly $1.5 billion to $2 billion in play.
Matt Hewitt
analystUnderstood. Thanks very much.
Brendan Smith
analystThanks a lot for fielding the questions, folks, and congratulations on the quarter as well. Perhaps one more, actually, on this whole total revenue mix discussion. I realize a few have come up already. I suppose, just given the recent clinical progress and the upcoming progress with the partners as well, could you give us a sense of how that total revenue mix ultimately shakes out across the next couple of years? I know there are plenty of moving parts, even at a high level. If we take slides 17 and 18, for instance, as a reference, is it reasonable to think milestones stay the largest bucket through next year, but I guess when does that switch to majority royalties? Could that arrive in 2028, 2029? And then, should we expect milestones to begin tapering on a dollar basis, or rather keep expanding in tandem? Anything at a high level about how that mix evolves would be great.
Kurt Gustafson
executiveSure, I can field that one, and Matt, perhaps if you have more color, you can add it. I think you sort of laid out how we see this unfolding, correct? Across the next couple of years, milestones, we would anticipate, would remain the largest contributor to our overall revenue stream. The next sort of major product that comes along that I think begins to push those royalties into becoming a bigger part of the growth story would be Immunovant's 1402, right? If I look at the forecasts out there for that program, it appears that might begin in late 2028 and then ramp from there. I will say, though, that, regarding the other lines, we did see sort of an almost kind of a low point in service revenue last year, and I think you've seen that line item grow, and that I think will add to the revenue growth. I also think Amechi here has discussed what our specific guidance is with xPloration, 2 to 3 this year and then doubling and then doubling again. I think you're actually going to see contributions from multiple of these revenue lines that will add to that overall growth. I guess the simple answer is, across the next couple of years, yes, we would expect that milestone would be the sort of the largest contributor to the overall revenue picture.
Matt Foehr
executiveOne more piece I'd put on top of that, Brendan, and that's the value we generate through technology licenses. Clearly, we hold technologies that deliver meaningful, lasting, competitive advantage, and licensing will remain part of what we do—whether that's our standard tech licensing or the service work Kurt mentioned, where we're heavily engaged not just on the conventional antibody side but also in ion channel screening. We also pointed to our entrepreneur enablement licensing, which opens up other kinds of upside, and then, naturally, the asset-based deals we've struck periodically. Beyond all that, we see chances for additional licensing where the data layers we possess and can build create further opportunities too. My sense is there's plenty of opportunity in this area, and it's something we're genuinely excited about.
Brendan Smith
analystUnderstood. That's really useful, everyone. Appreciate it.
Kurt Gustafson
executiveYes, thanks.
Michael King
analystMorning, everyone, and thanks for taking my question. I also want to say congratulations on a fantastic quarter, and thank you for running our model — that's always appreciated. A lot of questions have already come up and been answered about the revenue mix. I'd like to dig into it a bit more specifically. When you've got a pipeline-in-a-product type of opportunity like TEV-408, help us understand: do these kinds of products each come with separate milestones for individual indications, or is it purely a royalty arrangement, or does it just depend on what type of agreement you've signed with them?
Matt Foehr
executiveMike, thanks for the question. You're right to point out pipeline-in-a-product assets. Having spent over fifteen years heavily involved in pharmaceutical royalties, I can tell you that a true distinguishing feature of an asset that pays royalties is when that single product functions as an entire pipeline—when collaborators are chasing several indications and targeting various therapeutic areas. Naturally, much of our licensing work is done with the goal of generating meaningful shareholder value through royalties. All of these considerations—approval milestones across different geographies, clinical trial initiations—are part of how we evaluate things. Our agreements occasionally include milestones tied to several indications or several markets, though I would note that the partnerships in our portfolio vary considerably. Negotiations are a constant part of this, though some licensed assets do bring us milestone payments tied to things like various trial launches, additional indications, label or geographic expansions, and so on. It varies across deals, and I'm not able to discuss any particular contract, but situations of that kind do exist within our portfolio.
Michael King
analystThat one's tied to the specific deal, which is helpful. Let me pivot to xPloration briefly. Other people have told us stories about AI-driven labs that essentially operate on their own — from designing a test, to ordering reagents, to carrying out the experiments, to producing the data, and so on. I'm curious how much AI you plan to incorporate into xPloration as time goes on, and how you weigh customer requirements regarding integration with those kinds of automated lab systems.
Matt Foehr
executiveMike, I'll offer a remark, a broad, high-level one, and then Amechi can speak in more detail about the way xPloration gets used in AI. Just at a high level again — and people who know us well would agree — we have strong faith in AI. For a long time we've viewed AI as an enormous tailwind for the industry. Our partners are aware of that; we rolled out our OmniDeep platform quite a few years ago; it's our set of AI tools threaded across our platform. High-quality data relevant to human therapeutics is one thing AI requires, and our platform produces precisely that. Our business model is inherently AI friendly, and I believe people recognize that about us, correct? Investment in that area has grown, particularly at the compute layer. As discovery grows more iterative and more data intensive, we view that as a wonderful development for the kinds of technologies we have built and are building, and mostly thanks to the vantage point we hold on the industry, we have considerable conviction about that, and I think it places us very well, not only for our transgenic animals that can generate these enormous data layers that are relevant, extremely relevant to novel drug discovery, but for xPloration too. I'll sort of hand it to Amechi, and let him say a bit more on that.
Amechi Nwachuku
executiveThanks, Matt. I believe you handled that pretty thoroughly, though let me build on the details around xPloration — since it moves quickly, since it's extremely user-friendly and sturdy, and since it handles a great deal of volume, it could potentially slot in very nicely for discovery workflows that are AI-enabled; we definitely aim to get it into those users' hands and to let them take advantage of what xPloration offers them.
Michael King
analystGreat, thanks for taking the questions.
Amechi Nwachuku
executiveThanks, Mike.
Matt Foehr
executiveThank you, Mike.
Matt Foehr
executiveThanks, Josh. On the question of timing when bigger companies buy out smaller partners — something we've witnessed a handful of times over the last few years — the way our licenses are set up ties the economics to the asset itself. That's the piece that endures. We've given a great deal of consideration to how those licenses are structured, and the royalties are tied as well to the patents our partners file on molecules discovered using our technology, but put simply, those economics stay with the asset, even in a case where a larger partner holding an existing license makes the acquisition. Then
Amechi Nwachuku
executiveRegarding the question about the xPloration revenue mix, we are still at an early stage in the platform's life cycle for xPloration, so the majority of revenue at present comes from instrument placement — that initial revenue stream. As time goes on, we could potentially see recurring revenue grow in importance and become a larger contributor as customers use the platform with greater regularity and as we broaden the applications offered on it. Maybe I can just fit in one more quick question. I realize it's early, as you mentioned, but have you observed any kind of dynamics unfolding within the xPloration platform where partner dynamics utilize this xPloration platform downstream, and that then leads to an additional partnership later on for, I suppose, the end product that the xPloration platform gives you? Yes. XPloration is highly synergistic with the remainder of our OmniAb business. Clearly, for roughly the last year and a half, we have been operating in the partner access program, essentially all of our placements historically have been with partners, and we are now broadening to general availability. We are seeing that feedback loop function very effectively between the xPloration business and the traditional licensing business. It is quite interesting. Among the frequent comments we hear from antibody discovery teams when we initially place the instrument, once they have grasped the fundamentals, is that they return to us and say, "Oh, what else might we do with this platform? How about we try this?" That is when we find ourselves involved in that scientist-to-scientist collaboration that is quite fulfilling for their teams and our teams, and exciting to be part of. Awesome, thanks for taking the question. Congrats on the quarter. Yep.
Matt Foehr
executiveThank you.
Matt Foehr
executiveThank you. I want to express appreciation to everyone for being on today's call, and for the questions and engagement you've brought. I'd also like to express appreciation to our team at OmniAb for the hard work they keep putting in on our innovative platforms and our licensing efforts, and for the attention they give our partners and customers; this is a genuinely exciting moment for the business and for the industry, and we're eager to talk through our fourth quarter and full-year 2026 financial results in a few months. Until then, we'll be attending several investor conferences that are coming up, among them the Stifel Healthcare Conference on November 11th, the Truist Biopharma Symposium on November the 12th, and the Craig-Hallum Investor Conference on November 17th. Each of those takes place in New York City. I'll be in London as well for the Jefferies Healthcare Conference from November 16th to the 19th; we hope to see plenty of you while we're out at those events, and that brings our call today to a close. Thanks once more, and have a wonderful morning and a wonderful remainder of the day.
Operator
operatorThis concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.